Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles

IntroductionImproved therapies for glioblastoma (GBM) are desperately needed and require preclinical evaluation in models that capture tumor heterogeneity and intrinsic resistance seen in patients. Epigenetic alterations have been well documented in GBM and lysine-specific demethylase 1 (LSD1/KDM1A)...

Full description

Bibliographic Details

Published in:	Frontiers in Neurology
Main Authors:	Lea M. Stitzlein, Achintyan Gangadharan, Leslie M. Walsh, Deokhwa Nam, Alexsandra B. Espejo, Melissa M. Singh, Kareena H. Patel, Yue Lu, Xiaoping Su, Ravesanker Ezhilarasan, Joy Gumin, Sanjay Singh, Erik Sulman, Frederick F. Lang, Joya Chandra
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Subjects:	histone demethylase inhibitors epigenetics lysine specific demethylase (KDM) glioblastoma drug resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1112207/full